Danaher Corporation (LON:0R2B)
193.95
-5.41 (-2.71%)
At close: Aug 1, 2025
FARO Technologies Revenue
Danaher had revenue of $5.94B USD in the quarter ending June 27, 2025, with 3.36% growth. This brings the company's revenue in the last twelve months to $24.01B, up 1.89% year-over-year. In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%.
Revenue (ttm)
$24.01B
Revenue Growth
+1.89%
P/S Ratio
6.08
Revenue / Employee
$381.16K
Employees
63,000
Market Cap
106.54B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Danaher News
- 8 days ago - Investors decided the good outweighs the bad with Danaher, says Jim Cramer - CNBC
- 8 days ago - Danaher Q2 2025 Update - Seeking Alpha
- 10 days ago - Danaher Stock: Attractively Valued And Poised For Growth Acceleration - Seeking Alpha
- 10 days ago - Danaher Raises 2025 Earnings Outlook - The Motley Fool
- 10 days ago - Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline - Benzinga
- 10 days ago - Danaher raises full-year EPS guidance to $7.70-$7.80 amid robust bioprocessing growth and portfolio resilience - Seeking Alpha
- 10 days ago - Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Danaher (DHR) Q2 2025 Earnings Call Transcript - The Motley Fool